These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141 [TBL] [Abstract][Full Text] [Related]
10. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes]. Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445 [TBL] [Abstract][Full Text] [Related]
11. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261 [TBL] [Abstract][Full Text] [Related]
13. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity. Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275 [TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Itoh K; Tilden AB; Balch CM Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040 [TBL] [Abstract][Full Text] [Related]
15. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743 [TBL] [Abstract][Full Text] [Related]
16. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198 [TBL] [Abstract][Full Text] [Related]
17. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. Aebersold P; Hyatt C; Johnson S; Hines K; Korcak L; Sanders M; Lotze M; Topalian S; Yang J; Rosenberg SA J Natl Cancer Inst; 1991 Jul; 83(13):932-7. PubMed ID: 2067036 [TBL] [Abstract][Full Text] [Related]
18. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342 [TBL] [Abstract][Full Text] [Related]
19. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients. Pandolfi F; Boyle LA; Trentin L; Oliva A; Kurnick JT Clin Exp Immunol; 1994 Jan; 95(1):141-7. PubMed ID: 8287599 [TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]